Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 4

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 4
---
 Mapping System. Meanwhile, phase one of the ADVANTAGE AF clinical trial further confirmed the safety and efficacy of the FARAPULSE PFA System and is intended

#### ii2025 Proxy Statement

#### A Letter from our CEO
to support an indication expansion for patients with persistent AF. We recently completed enrollment in another trial, AVANT GUARD, to evaluate the FARAPULSE PFA System as a first-line treatment for persistent AF.

#### Two technologies, one efficient procedure
Our ability to serve patients with AF expanded when the U.S. Centers for Medicare and Medicaid Services (CMS) approved a new payment for concomitant cardiac ablation and LAAC procedures. This new payment makes it possible for more patients in the U.S. to undergo and receive coverage for cardiac ablation and LAAC procedures simultaneously and avoid multiple procedures, when physicians feel this is the best course of action. With this approach, patients may be able to be taken off oral anticoagulation therapy earlier, and hospitals can optimize their workflow.

#### Addressing Unmet Needs to Improve Patient Care
Across the specialties we serve, we are always collaborating with customers to identify clinical challenges in need of solutions. This year we worked to address those unmet needs in a variety of ways:

• Devising meaningful solutions: In patients with coronary artery disease, coronary stenting is commonly used to restore blood flow to the heart, but in some cases those stented vessels become blocked or narrowed again. We received FDA approval for our AGENT™ Drug-Coated Balloon (DCB), which we designed to reopen those vessels, then transfer a therapeutic drug to the vessel wall to help prevent reoccurrence. Already in use in Europe and Japan, the AGENT DCB is the first coronary drug-coated balloon in the U.S.

• Expanding therapy indications to treat more patients: Based on clinical trial data, the FDA approved an expanded indication for our WaveWriter™ Spinal Cord Stimulator Systems for the treatment of chronic low back and leg pain in people who have not had back surgery, commonly referred to as non-surgical back pain. This will provide physicians more choices to help their patients find relief.

• Delivering actionable insights with AI: We are harnessing the power of AI and digital technologies to improve diagnostics and provide decision support. For example, our AI-powered BeatLogic™ Cardiac Algorithm analyzes data from wearable cardiac devices to detect variations in heart rhythms so doctors can take preventive action quickly. Our AVVIGO+™ Multi-Modality System is the first